Phase 1 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• The person joining (or their legal representative, if needed) must be willing and able to sign a consent form for the study.
• Participants must be 18 years of age or older on the day they sign the consent form.
• Participants must have cancer that can be measured on scans, or certain types that meet non-measurable disease criteria as defined by the trial (confirm with trial site).
• Participants must have a general health and activity level rated at 0 or 1 on a standard scale used by doctors to assess how much cancer affects daily functioning (confirm with trial site).
• Participants must have a life expectancy of more than 12 weeks.
• Participants must have kidneys, liver, blood, and other organs working well enough to meet the trial's defined standards (confirm with trial site).
• Participants must be willing and able to attend all scheduled visits, including follow-up appointments, and to follow the trial procedures.
• Participants must be willing and able to have imaging scans as required by the trial.
• Participants must be willing to provide blood samples for research purposes related to the trial.
• Participants must be able to swallow tablets or capsules whole.
• Previous treatment with an approved non-selective PARP inhibitor (a type of cancer drug) is allowed, but only in the dose-escalation part of the trial.
• Participants must have a confirmed diagnosis — based on tissue testing — of advanced or metastatic breast cancer, prostate cancer, ovarian cancer, or pancreatic cancer, along with specific gene changes as defined by the trial (confirm with trial site).
• Participants must have received prior cancer treatment as specified by the trial, depending on the type of cancer (confirm with trial site).
• People with known cancer that has spread to the brain — whether causing symptoms or not — confirmed by an MRI scan, may be eligible for the dose-expansion part of the trial (confirm with trial site).

Who may not be able to join:

• People who have, or show signs of, certain serious blood or bone marrow conditions called myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML).
• People who have previously been treated with a PARP1-selective inhibitor (a specific type of targeted cancer drug).
• People who have received cancer treatment — including experimental treatments — within 2 to 4 weeks before starting the trial, depending on the type of treatment (confirm with trial site).
• People who have had radiotherapy within 2 weeks before starting the trial, or who have a history of a lung condition caused by radiation called radiation pneumonitis.
• People who have a weakened immune system, or who are taking steroid medications above a certain dose, or any other immune-suppressing medication within 7 days before the first dose.
• People who have received a live or live-attenuated vaccine within 30 days before the first dose (non-live vaccines are allowed).
• People who have had an organ or tissue transplant from another person.
• People who have an active autoimmune disease that has required treatment with medicines such as immunosuppressants or steroids in the past 2 years.
• People who have a history of, or currently have, a non-infectious lung inflammation condition (pneumonitis or interstitial lung disease) that required steroid treatment.
• People with severe, ongoing nausea and vomiting, or gut problems that may affect how the study drug is absorbed by the body.
• People who have had major surgery, an open biopsy, or a significant injury within 28 days before starting the trial.
• People who have an active infection requiring treatment, or another serious uncontrolled illness.
• People with a known history of HIV infection.
• People with a known history of Hepatitis B, or currently active Hepatitis C infection.
• People with liver cirrhosis (significant scarring of the liver).
• People with a clinically significant lung condition.
• People with significant heart problems or serious heart disease.
• People with a wound, ulcer, or bone fracture that has not yet healed within 28 days before the first dose.
• People with any medical condition, past or current, or abnormal test results that could affect the trial results or their ability to participate for the full study period.
• People who are capable of becoming pregnant and have a positive pregnancy test within 72 hours before starting the trial.
• People with a known psychiatric condition or substance use disorder that would affect their ability to participate in the trial as required.
• People who have lost more than 5% of their body weight in the 8 weeks before starting the trial.
• People with a known allergy or sensitivity to any ingredient in the study drug DSB2455.
• People who have received radiation to the lung above a certain dose level within 6 months before the first dose (confirm with trial site).
• Other disease-specific criteria as outlined in the trial protocol (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.